Oncotarget

Research Papers:

Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities

Lei Li, Huimin Bai, Jiaxin Yang, Dongyan Cao and Keng Shen _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:15136-15148. https://doi.org/10.18632/oncotarget.14767

Metrics: PDF 2074 views  |   HTML 3143 views  |   ?  


Abstract

Lei Li1, Huimin Bai1, Jiaxin Yang1, Dongyan Cao1, Keng Shen1

1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Correspondence to:

Keng Shen, email: [email protected]

Keywords: ovarian cancer, tumor heterogeneity, invasion/migration, copy number variation (CNV), genetic targets

Received: December 17, 2015     Accepted: January 10, 2017     Published: January 20, 2017

ABSTRACT

Ovarian cancer has the worst prognosis of any gynecological malignancy, and generally presents with metastasis at advanced stages. Copy number variation (CNV) frequently contributes to the alteration of oncogenic drivers. In this study, we sought to identify genetic targets in heterogeneous clones from human ovarian cancers cells. We used array-based technology to systematically assess all the genes with CNVs in cell models clonally expanded from A2780 and SKOV3 ovarian cancer cell lines with distinct highly and minimally invasive/migratory capacities. We found that copy number alterations differed between matched highly and minimally invasive/migratory subclones, differentially affecting specific functional processes including immune response processes, DNA damage repair, cell cycle and cell proliferation. We also identified seven genes as strong candidates, including DDB1, ERCC1, ERCC2, PRPF19, BCAT1, CDKN1B and MARK4, by integrating the above data with gene expression and clinical outcome data. Thus, by determining the molecular signatures of heterogeneous invasive/migratory ovarian cancer cells, we identified genes that could be specifically targeted for the treatment and prognosis of advanced ovarian cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14767